Last updated: February 14, 2026
Product Overview
NDC 00115-1320 corresponds to Kalydeco (ivacaftor), a CFTR potentiator approved for cystic fibrosis (CF) patients aged 2 years and older with specific genetic mutations. Approved by the FDA in 2012, Kalydeco marks a significant advance, targeting the underlying cause of CF in mutation-specific populations.
Market Size and Demographics
The cystic fibrosis market consists of approximately 30,000 diagnosed patients in the United States. The distribution of genetic mutations affects the subset eligible for Kalydeco, estimated at around 5,000-8,000. The global CF population approximates 70,000, expanding market prospects.
Competitive Landscape
Kalydeco faces competition primarily from other CFTR modulators such as Orkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), and Trikafta (elexacaftor/tezacaftor/ivacaftor). Trikafta, approved in 2019, exhibits broader mutation coverage and has captured significant market share.
Pricing Structure and Revenue
Kalydeco's pricing varies by dosage and treatment duration. Current wholesale acquisition costs (WAC) are approximately:
| Dosage |
Monthly Cost |
Annual Cost |
| 150 mg |
$8,500 |
$102,000 |
| 75 mg |
$4,250 |
$51,000 |
Therapies are often prescribed with tailored dosing, averaging about 150 mg twice daily. Aggregate annual revenue is estimated at $350-400 million in the U.S., with global revenues approaching $700 million, considering prescription volume and pricing.
Market Trends and Adoption
Kalydeco adoption depends on mutation prevalence, physician familiarity, and insurance reimbursement. Breakthroughs like Trikafta, covering nearly 90% of CF mutations, have shifted treatment paradigms, diminishing Kalydeco's growth ceiling in mutation-specific niches.
Regulatory and Policy Impacts
Recent policies stress affordability, with payers negotiating discounts and value-based agreements. Patent expirations are unlikely before 2030, suggesting continued exclusivity and pricing stability in the short to medium term.
Price Projection Outlook
Over the next five years, Kalydeco’s unit price is expected to remain stable due to its orphan drug status and patent protections. Volume growth may plateau with the broader use of Trikafta. Price erosion, if any, would likely stem from increased biosimilar competition or policy-driven generic entry, which is not anticipated before 2030.
Key Factors Influencing Price and Market
- Increasing diagnosis and mutation testing rates expand the treatable patient base.
- Broader mutation coverage therapies like Trikafta may reduce Kalydeco’s market share.
- Market access and reimbursement policies could influence net pricing.
- Patent protections preserve pricing for the foreseeable future.
Key Takeaways
- Kalydeco's current annual revenue in the U.S. hovers around $350-400 million, with global revenues near $700 million.
- Pricing remains stable due to orphan drug status; major price declines unlikely before patent expiry (~2029-2030).
- Broader-acting CFTR modulators challenge Kalydeco’s market position, potentially limiting future growth.
- Market expansion depends on increased mutation testing and new indications.
- Policy and reimbursement strategies will influence net pricing but less so the list price in the near term.
FAQs
1. How does Kalydeco's market share compare with newer CFTR modulators?
Kalydeco primarily serves mutation-specific populations. Trikafta now dominates therapy for broader mutation groups, capturing a larger share of the overall CF market.
2. What factors could lead to price reductions before patent expiry?
Introduction of biosimilars, policy-driven price negotiations, and increased payer pressure on high-cost orphan drugs.
3. Will Kalydeco remain a profitable product long-term?
Yes, due to patent protection, limited competition for its specific indications, and high treatment costs.
4. How is the market expected to change with new therapies?
The market will shift toward drugs with broader mutation coverage, reducing dependence on mutation-specific therapies like Kalydeco.
5. Are there upcoming regulations that could impact pricing?
Potential regulatory changes favoring drug affordability and generic entry could affect pricing, but significant impacts are unlikely before 2030.
Citations
- U.S. Food and Drug Administration. (2012). FDA approves Kalydeco for cystic fibrosis.
- IQVIA. (2022). U.S. prescription drug data.
- Cystic Fibrosis Foundation. (2022). Patient population estimates and mutation distributions.
- Evaluate Pharma. (2022). CFTR modulator pipeline and market forecasts.
- CMS and policy reports. (2022). Orphan drug pricing and reimbursement landscape.
